Abstract
Background Recent studies have intensively explored the potential antidepressant effects of psilocybin. However, important variables such as previous experience, repeated administration, setting and sex remain underexplored. This study describes the acute psilocybin experience and long-term effects in a small sample of healthy individuals.
Methods In a double-blind, placebo-controlled, cross-over study, 40 healthy participants (20 females, mean age 38, sd 8) received two doses of psilocybin 0.26 mg/kg per os at least 56 days apart (mean 354 days) in two study arms (EEG and fMRI). Near half of participants had experience with psychedelics. The Altered State of Consciousness Scale (ASC) and a visual analogue scale (VAS) on emotional valence of the phenomenology assessed acute phenomenology. The Persisting Effects Questionnaire (PEQ) assessed long- term effects. Venous blood samples were taken to measure serum psilocin levels.
Results All results were independent of previous experience, sex, EEG or fMRI arm/setting. Acute psychedelic effects were of moderate intensity on ASC. The VAS showed mostly pleasant and fluctuating, and only one unpleasant only experience. All experiences resolved in a positive or neutral state at the end of the session. Psilocybin induced sustained positive effects on all domains of the PEQ, with negligible negative effects. Oceanic Boundlessness and Visual Restructuralization were associated with positive effects on PEQ. Contrary to expectations, Dread of Ego Dissolution, typically associated with fearful experiences, was not associated with PEQ negative outcomes. The type of experience (pleasant or mixed) did not correlate with the intensity or direction of the lasting effect; however, peak experiences culminating in a positive mood were associated with positive long- term effects.
Conclusion In our sample repeated administration of psilocybin to healthy volunteers, induces positive, lasting effects. This underscores the psychological safety of psilocybin in a laboratory setting and supports its repeated use in clinical trials. In particular, challenging or anxiety-provoking experiences in controlled environments did not lead to adverse long-term outcomes.
Clinical trial registration: EudraCT 2012-004579-37, https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-004579-37/CZ.
Competing Interest Statement
T.P., M.B., F.T. and J.H. declare to have shares in Psyon s.r.o.. T.P., M.B., F.T. and J.H. founded the PSYRES-Psychedelic Research Foundation and have shares in Spolecnost pro podporu neurovedniho vyzkumu s.r.o.. T.P. reports consulting fees from GH Research and CB21-Pharma outside the submitted work. T.P., V.V., M.V. and F.T. are involved in Compass Pathways and/or MAPS clinical trial with psilocybin/MDMA trials outside the submitted work. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Clinical Trial
EudraCT 2012-004579-37
Funding Statement
This work was supported by grant from Czech Health Research Council (project NU21- 04-00307), Czech Science Foundation (projects 20-25349S), Ministry of the interior of the Czech Republic (project VK01010212), Long-term conceptual development of research organization (RVO 00023752), and Specific University Research, Czech Ministry of Education, Youth and Sports (project 260648/SVV/2024), ERDF-Project Brain dynamics, No. CZ.02.01.01/00/22_008/0004643, project VVI CZECRIN (LM2023049) and Charles University research program Cooperatio-Neurosciences and private funds obtained via PSYRES, Psychedelic Research Foundation (https://psyresfoundation.eu).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee of National Institue of Mental Health, Topolova 648, 25067 Klecany, Czech Republic gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
